Graft Survival Similar for Kidneys From Octogenarians

This article originally appeared here.
Share this content:
Graft Survival Similar for Kidneys From Octogenarians
Graft Survival Similar for Kidneys From Octogenarians

TUESDAY, Aug. 15, 2017 (HealthDay News) -- Graft survival is similar for recipients of kidneys from >80-year-old donors and donors aged ≤60 years, according to a study published online Aug. 9 in the American Journal of Transplantation.

Piero Ruggenenti, M.D., from the Clinical Research Centre for Rare Diseases Aldo e Cele Daccò in Bergamo, Italy, and colleagues compared graft survival for 37 recipients of one or two histologically evaluated kidneys from >80-year-old donors with 198 reference-recipients of nonhistologically evaluated single grafts from ≤60-year-old donors.

The researchers found that two recipients (5.4 percent) and 10 reference-recipients (5.1 percent) required dialysis over a median of 25 months (crude and donor age- and sex-adjusted hazard ratios, 1.55 [95 percent confidence interval, 0.34 to 7.12; P = 0.576] and 1.41 [95 percent confidence interval, 0.1 to 19.54; P = 0.798]). Similar outcomes were confirmed in shared frailty analyses in a 1-to-2 propensity score study comparing recipients with 74 reference-recipients matched by center, year, and donor and recipient sex and age. Over 84-month follow-up, serum creatinine was similar across groups. Recipients had shorter waiting times than reference-recipients and matched reference-recipients (7.5 versus 36 and 40 months, respectively; both P < 0.0001). Similar adverse events were seen across groups.

"Biopsy-guided allocation of kidneys from octogenarian donors permits further expansion of the donor-organ pool and faster access to a kidney transplant, without increasing the risk of premature graft failure," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »